ATE286873T1 - Ester des l-carnitin oder alkanoyl l-carnitin zur verwendung als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe - Google Patents

Ester des l-carnitin oder alkanoyl l-carnitin zur verwendung als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe

Info

Publication number
ATE286873T1
ATE286873T1 AT00922852T AT00922852T ATE286873T1 AT E286873 T1 ATE286873 T1 AT E286873T1 AT 00922852 T AT00922852 T AT 00922852T AT 00922852 T AT00922852 T AT 00922852T AT E286873 T1 ATE286873 T1 AT E286873T1
Authority
AT
Austria
Prior art keywords
carnitine
alkanoyl
esters
cationic lipids
therapeutic substances
Prior art date
Application number
AT00922852T
Other languages
English (en)
Inventor
Claudio Pisano
Maria Ornella Tinti
Mose Santaniello
Luciana Critelli
Giovanni Salvatori
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE286873T1 publication Critical patent/ATE286873T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00922852T 1999-04-13 2000-04-11 Ester des l-carnitin oder alkanoyl l-carnitin zur verwendung als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe ATE286873T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
PCT/IT2000/000137 WO2000061543A2 (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines

Publications (1)

Publication Number Publication Date
ATE286873T1 true ATE286873T1 (de) 2005-01-15

Family

ID=11406659

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00922852T ATE286873T1 (de) 1999-04-13 2000-04-11 Ester des l-carnitin oder alkanoyl l-carnitin zur verwendung als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe
AT03020049T ATE317257T1 (de) 1999-04-13 2000-04-11 Verwendung von estern von l-carnitinsäure oder von alkanoyl l-carnitinsäure als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03020049T ATE317257T1 (de) 1999-04-13 2000-04-11 Verwendung von estern von l-carnitinsäure oder von alkanoyl l-carnitinsäure als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe

Country Status (34)

Country Link
US (4) US6797281B1 (de)
EP (3) EP1435232A1 (de)
JP (2) JP4703855B2 (de)
KR (2) KR100684378B1 (de)
CN (2) CN1263730C (de)
AT (2) ATE286873T1 (de)
AU (2) AU776301B2 (de)
BG (3) BG65501B1 (de)
BR (2) BRPI0017460B1 (de)
CA (2) CA2650202C (de)
CZ (1) CZ302628B6 (de)
DE (2) DE60017388T2 (de)
DK (2) DK1426044T3 (de)
EA (2) EA004459B1 (de)
EE (2) EE05514B1 (de)
ES (2) ES2258688T3 (de)
HK (2) HK1045145B (de)
HR (1) HRP20010740B1 (de)
HU (1) HU229366B1 (de)
IL (4) IL145765A0 (de)
IS (2) IS2476B (de)
IT (1) IT1306129B1 (de)
ME (2) ME00113B (de)
MX (1) MXPA01010359A (de)
NO (2) NO327742B1 (de)
NZ (2) NZ515270A (de)
PL (2) PL204418B1 (de)
PT (2) PT1183228E (de)
RS (3) RS52682B (de)
SI (2) SI1426044T1 (de)
SK (2) SK288246B6 (de)
TR (2) TR200202358T2 (de)
WO (1) WO2000061543A2 (de)
ZA (1) ZA200109291B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE10113446A1 (de) † 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
ES2421714T3 (es) * 2002-06-26 2013-09-05 Medigene Ag Una preparación de liposomas catiónicos que comprende un taxano
AU2003280505B2 (en) 2002-06-26 2009-01-15 Syncore Biotechnology Co., Ltd Method of producing a cationic liposomal preparation comprising a lipophilic compound
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
WO2006094203A1 (en) * 2005-03-02 2006-09-08 Northeastern University Mitochondriotropic phospholipid vesicles
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CA2617873A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
AU2006277879A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Microparticle compositions of the topoisomerase I inhibitor 7-tert-butoxyiminomethylcamptothecin
WO2008024389A2 (en) * 2006-08-23 2008-02-28 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
US20100104625A1 (en) * 2007-02-16 2010-04-29 Cornell University Biodegradable compositions and materials
US20100204432A1 (en) * 2007-05-28 2010-08-12 Husam Younes Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
WO2009114763A2 (en) 2008-03-13 2009-09-17 Perkinelmer Las, Inc. Enzymatic substrates for multiple detection systems
EP2532649B1 (de) * 2011-06-07 2015-04-08 Incella GmbH Aminolipide, deren Synthese und Verwendungen davon
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
TW201525142A (zh) 2013-03-15 2015-07-01 Perkinelmer Health Sci Inc 關於用於溶酶體儲積症之測試的化合物及方法
KR20180114946A (ko) 2016-03-02 2018-10-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 sting 활성화 나노백신
US11103588B2 (en) 2017-06-06 2021-08-31 Wayne State University Methods and compositions relating to carnitine-derived materials
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
ATE137242T1 (de) * 1990-06-15 1996-05-15 Univ Wake Forest Kovalente-ther lipidnukleosid-konjugate
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
CA2163860A1 (en) * 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
EP0833667A4 (de) * 1995-06-07 2001-11-21 Univ California Stabilisierung von polynukleotidkomplexen
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
WO1998004720A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
IL175366A (en) 2010-12-30
HK1045145A1 (en) 2002-11-15
EE05514B1 (et) 2012-02-15
DE60017388D1 (de) 2005-02-17
BRPI0017460B1 (pt) 2016-04-19
JP4703855B2 (ja) 2011-06-15
NO20014985L (no) 2001-10-12
PL211710B1 (pl) 2012-06-29
BG105971A (en) 2002-08-30
IS2539B (is) 2009-09-15
AU2004224958B2 (en) 2007-11-22
IL185486A0 (en) 2008-01-06
US6797281B1 (en) 2004-09-28
CA2650202C (en) 2012-12-11
IS6095A (is) 2001-09-28
YU70201A (sh) 2004-07-15
US7629003B2 (en) 2009-12-08
KR100798499B1 (ko) 2008-01-28
CN1823731A (zh) 2006-08-30
SK287253B6 (sk) 2010-04-07
CZ302628B6 (cs) 2011-08-10
IT1306129B1 (it) 2001-05-30
IL175366A0 (en) 2006-09-05
EE201100028A (et) 2011-08-15
EA200101076A1 (ru) 2002-04-25
JP2011042657A (ja) 2011-03-03
BG109876A (en) 2008-02-29
NZ528874A (en) 2005-09-30
SI1426044T1 (sl) 2006-04-30
EP1435232A1 (de) 2004-07-07
BG65312B1 (bg) 2008-01-31
ZA200109291B (en) 2002-08-16
EE05719B1 (et) 2014-08-15
CA2650202A1 (en) 2000-10-19
HK1045145B (zh) 2006-01-27
SK14312001A3 (sk) 2002-02-05
JP2002541238A (ja) 2002-12-03
EA006021B1 (ru) 2005-08-25
BR0009765B1 (pt) 2013-11-05
HUP0201446A2 (en) 2002-08-28
SK288246B6 (sk) 2015-03-03
EP1183228B1 (de) 2005-01-12
DE60025961T2 (de) 2006-08-17
CN1263730C (zh) 2006-07-12
HK1092732A1 (en) 2007-02-16
CZ20013617A3 (cs) 2002-02-13
EP1426044A1 (de) 2004-06-09
NO20085413L (no) 2001-10-12
NO336949B1 (no) 2015-11-30
ITRM990220A1 (it) 2000-10-13
ES2234591T3 (es) 2005-07-01
HUP0201446A3 (en) 2002-11-28
DE60025961D1 (de) 2006-04-20
NO327742B1 (no) 2009-09-14
CA2370143C (en) 2011-06-21
JP5420507B2 (ja) 2014-02-19
CA2370143A1 (en) 2000-10-19
KR20010113794A (ko) 2001-12-28
RS20090448A (en) 2010-06-30
EA200300745A1 (ru) 2003-12-25
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
AU776301B2 (en) 2004-09-02
RS50911B (sr) 2010-08-31
US20050079209A1 (en) 2005-04-14
EE200100518A (et) 2002-12-16
PL204418B1 (pl) 2010-01-29
ATE317257T1 (de) 2006-02-15
KR20060113799A (ko) 2006-11-02
DE60017388T2 (de) 2006-03-30
SI1183228T1 (en) 2005-04-30
KR100684378B1 (ko) 2007-02-20
HRP20010740A2 (en) 2002-10-31
TR200202358T2 (tr) 2002-12-23
IS8719A (is) 2008-03-07
CN1359370A (zh) 2002-07-17
IL145765A0 (en) 2002-07-25
WO2000061543A3 (en) 2001-01-11
ES2258688T3 (es) 2006-09-01
TR200102941T2 (tr) 2002-05-21
HU229366B1 (en) 2013-11-28
RS52682B (en) 2013-08-30
WO2000061543A2 (en) 2000-10-19
HRP20010740B1 (en) 2005-08-31
AU4312300A (en) 2000-11-14
NO20014985D0 (no) 2001-10-12
DK1426044T3 (da) 2006-06-12
AU2004224958A1 (en) 2004-11-25
DK1183228T3 (da) 2005-05-17
MEP24008A (en) 2010-06-10
PT1183228E (pt) 2005-04-29
BG65501B1 (bg) 2008-10-31
EP1426044B1 (de) 2006-02-08
EP1183228A2 (de) 2002-03-06
PT1426044E (pt) 2006-06-30
ME00113B (me) 2010-10-10
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
US20070190128A1 (en) 2007-08-16
BR0009765A (pt) 2002-01-02
CN100402017C (zh) 2008-07-16
IL145765A (en) 2007-07-04
IS2476B (is) 2008-12-15
US7585519B2 (en) 2009-09-08
EA004459B1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
ATE286873T1 (de) Ester des l-carnitin oder alkanoyl l-carnitin zur verwendung als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe
ATE283695T1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
AU4858796A (en) Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
DE69826674D1 (de) Zusammensetzung, l-carnitin oder alkanoyl l-carnitin und langkettige alkanole enthaltend
EP0396081A3 (de) Verwendung von Phosphatidylcarnitin zur Herstellung von Arzneimitteln mit therapeutischer Wirkung auf mit neuronalen Schädigungen verbundenen pathologischen Zuständen beim Menschen
AR013538A1 (es) Nuevos mitogenos especificos de osteoblastos, metodos para prepararlos y drogas que contienen tales compuestos
ATE272047T1 (de) Perfluorierte ester von alkanoyl l-carnitin zur herstellung von kationischen lipiden zur intrazellulären verabreichung pharmakologisch aktiver verbindungen
DE60008415D1 (de) Zusammensetzung die mindestens ein stickstoffmonoxid-synthase inhibitor und mindestens ein phospholipase a2 inhibitor enthält zur herstellung eines medikamentes
EP2033631A3 (de) Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1183228

Country of ref document: EP